Drone strike devastates Indian‑linked pharmaceutical complex
New Delhi. A Russian‑operated drone slammed into the Kusum Group’s manufacturing site in Sumy, Ukraine, reducing the main structure to rubble, killing an engineer and wounding multiple employees. The assault hit the plant several times, annihilating its engineering wing and triggering an immediate evacuation order.
Early estimates place the material loss at around Rs 400 crore, although the firm stresses that a comprehensive audit is still pending. Given the scale of the destruction, the factory is expected to stay shut for an undefined period.
Indian heritage, Ukrainian presence
The Kusum Group first entered the Ukrainian market in 1994, initially as a distributor of medicines sourced from India. By 2009 it had erected a full‑scale production complex in Sumy, complementing its 2007 manufacturing hub back home in India. Today the conglomerate markets more than 50 generic medicines across Ukraine, Uzbekistan, Kazakhstan and the Philippines, positioning itself as a Ukrainian pharma player with Indian roots.
Operations persisted through conflict – until now
Despite the ongoing war, the Sumy plant continued to supply essential drugs to patients locally and throughout the region. The latest drone barrage, however, has forced a complete halt to production and prompted the group to consider relocating vulnerable lines to its Indian facilities.
Ukrainian President Volodymyr Zelenskyy denounced the strike, confirming that a drone barrage targeted the pharmaceutical complex and resulted in a fatality. The incident highlights the growing peril faced by civilian and commercial infrastructure in active war zones.
Broader implications
The obliteration of the Sumy plant threatens the availability of key generic medicines in the area and raises serious concerns about the durability of cross‑border supply chains amid armed conflict. A thorough post‑incident assessment will gauge the full financial and operational repercussions for the Indian‑linked conglomerate.
